Learning from pediatric CAR-T development: insights from manufacturing unique patient doses
September 26, 2022
Sean Werner and Chris Brown
What valuable experiences from first generation cell therapies can the industry carry forward and apply to other indications, such as solid tumors? In this episode, Sean Werner and Chris Brown explore the most important lessons the industry has gleaned from pediatrics, and how they can inform the future of cell therapy manufacturing.
Firstly, can you both tell me a bit about the current work you do?
What lessons has the cell and gene therapy industry learned from pediatric therapies that can be applied to developing cell therapies for other indications?
When it comes to the development of cell therapies for these indications, what represents the cutting-edge regarding tools and technology?
What are the biggest current challenges regarding cost and funding?
From a supplier perspective, what has worked well – or doesn’t work well – when trying to solve customer challenges?
Looking to the future, what are the biggest lessons gleaned from first generation cell therapies?